Skip to content

Interaction Between White Potato Consumption and Meal Timing on Glycemic Response and Appetite in Adults

Interaction Between White Potato Consumption and Meal Timing on Glycemic Response, Subjective Appetite, and Energy Intake in Adults.

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07230951
Enrollment
30
Registered
2025-11-17
Start date
2025-10-30
Completion date
2027-10-31
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult, Appetite, Glycemic Response, Healthy, Mealtiming

Brief summary

The purpose of this study is to evaluate the interaction between white potato consumption and meal timing on glycemic response, subjective appetite, and energy intake in adults. The investigators hypothesize that white potatoes will modulate glycemic response, enhance satiety, and mitigate subsequent meal consumption and overall food intake when compared with meals containing low glycemic carbohydrates. Furthermore, they anticipate that the timing of white potato consumption will yield differential effects, with breakfast consumption exerting a more pronounced impact on satiety and subsequent food intake reduction compared to dinner consumption.

Detailed description

A randomized within-subject repeated measures experiment will be used to study the interaction between white potato consumption and meal timing on glycemic response, subjective appetite, and energy intake in adults. In Experiment 1, participants will consume, in a random order on separate mornings, one of six test meals consisting of an egg omelette and a test side of: (1) Oven-baked home fries, (2) Oven-baked white russet potatoes, (3) Deep-fried, quick serve fries, (4) Oven-baked fries, (5) Oven-baked cauliflower tots, or (6) no side. Acute glycemic response and subjective appetite will be measured at baseline and over 120-mins post treatment consumption. At 120-min, food intake will be evaluated via an ad libitum lunch. Rest of day food intake and glycemic response will be collected until the participant goes to bed. Blood glucose measurements will be collected using the Dexcom G7 continuous glucose monitoring system.

Interventions

OTHERNo Side

No side control (no caloric contribution).

OTHEROven-baked Home Fries

Oven-baked Home Fries (241 g; McCain Ltd.). Test treatments matched for calories (284 kcal)

OTHEROven-baked White Russet Potato

Oven-baked White Russet Potato (299 g). Test treatments matched for calories (284 kcal)

OTHEROven-baked Fries

Oven-baked Fries (201 g; McCain Ltd.). Test treatments matched for calories (284 kcal)

OTHERDeep Fried, Quick Serve Fries

Deep Fried, Quick Serve Fries (108 g; McCain Ltd.). Test treatments matched for calories (284 kcal)

OTHEROven-baked Cauliflower Veggie Tots

Oven-baked Cauliflower Veggie Tots (186 g; Green Giant). Test treatments matched for calories (284 kcal)

Sponsors

Alliance for Potato Research and Education
CollaboratorOTHER
Toronto Metropolitan University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* 18 - 65 years * within the healthy body weight range \[body mass index (BMI) between 18.5 - 24.9 kg/m2\].

Exclusion criteria

* have a previous diagnosis of diabetes and gastrointestinal, liver or kidney disease; * have had a major medical or surgical event within the past 6 months; * have had any significant weight fluctuation in the past 6-months; * are taking medication that may influence dependent measures; * are or have been on a diet within the past 6 months; * skip breakfast or are unable to consume test treatment food.

Design outcomes

Primary

MeasureTime frameDescription
Glycemic Response (Acute Phase)Change from baseline (measured at baseline (0-minute), 15-minute, 30-minute, 60-minute, 90-minute, and 120-minute post-treatment consumption).Blood glucose (mmol/L). Blood glucose concentrations will be measured using a Dexcom G7 CGM system.
Rest-of-day Blood GlucoseContinuous measurements for 24 hours post-treatment consumption.Blood glucose (mmol/L). Rest-of-day blood glucose concentrations will be determined using a Dexcom G7 CGM system.
Ad Libitum Food IntakeAt 120 minutes post-treatment consumptionLunch pizza meal. Food intake will be determined by weighing the meal before and after serving. The net weight of the test meal will be converted to calories.

Secondary

MeasureTime frameDescription
Subjective AppetiteChange from baseline (measured at baseline (0-minute), 15-minute, 30-minute, 60-minute, 90-minute, and 120-minute post-treatment consumption).A visual analogue scale (VAS) with four questions will be administered to assess desire to eat, fullness, hunger, and prospective food consumption. Individual questions will be used to form a composite score. Each VAS will be administered via a digital software application (Express VAS, Toronto, Ontario, Canada) on a Dell tablet where participants will place an 'X on the VAS line (100 unit scale).
Rest-of-day Food IntakeFor the rest of the day following test session completion (1 day)Participants will be sent home with a rest-of-the-day food intake recall sheet to record their snacks, meals, and beverages. Rest of day food log.
Subjective EmotionsChange from baseline (measured at baseline (0-minute), 15-minute, 30-minute, 60-minute, 90-minute, and 120-minute post-treatment consumption).A visual analogue scale (VAS) with thirteen questions will be administered to assess subjective emotions and mood (aggression, anger, excitement, disappointment, happiness, upset, frustration, alertness, sadness, tension, exhaustion, calmness, and sleepiness). Individual questions will be used to form a composite emotion score. Each VAS will be administered via a digital software application (Express VAS, Toronto, Ontario, Canada) on a Dell tablet where participants will place an 'X on the VAS line (100 unit scale).

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026